Eczema, or atopic dermatitis, affects roughly 10% of adults and 25% of children in the US. Standard treatment includes moisturizers, topical steroids, and antihistamines. For moderate-to-severe eczema, newer options include dupilumab and other biologics that target specific immune pathways, along with JAK inhibitors in pill form.
What's actually going on in research
Trials are testing new JAK inhibitors — both pills and topical creams — that block inflammation more precisely. Biologics targeting IL-13, IL-31, and other immune signals are in late-stage testing. Researchers are also studying the skin microbiome, barrier-repair treatments, and better approaches for children and people with darker skin tones where eczema can be harder to assess.
JAK inhibitors
Several pills and creams that block JAK enzymes are now FDA-approved or in late-stage trials. They offer fast itch relief and may work when biologics don't, though long-term safety monitoring continues.
Targeted biologics
Drugs targeting IL-13 alone, or IL-31 for itch, are showing strong results in Phase 3 trials. These may become alternatives to dupilumab or options for people who don't respond to current biologics.
Microbiome therapies
Trials are testing live bacteria sprays and creams designed to restore healthy skin microbes. Early results suggest they may reduce flares by crowding out Staph aureus, which worsens eczema.
What to know before you search
Eligibility often depends on eczema severity, body surface area affected, recent treatment history, and whether topical steroids have been tried.
What types of trials are currently open
- Treatment trials — Testing new JAK inhibitors, biologics, or combination treatments to see if they clear eczema better or faster than current drugs.
- Topical trials — Studies of new creams or ointments, including JAK inhibitors and barrier-repair formulas, often for mild-to-moderate eczema.
- Pediatric trials — Testing safety and dosing of new treatments in infants and children, where eczema often starts.
- Itch and quality-of-life trials — Focused on treatments that relieve itch or improve sleep and daily function, even if skin appearance doesn't fully clear.
- Microbiome studies — Testing whether live bacteria, prebiotics, or other microbiome interventions can prevent flares or reduce reliance on steroids.
Recently added Eczema trials
The LITTLE OWLS Study (in German: "Kleine Eulen OWL"): Exploring the Early-life Microbiome Development and Physical and Mental Health Outcomes During Childhood.
The LITTLE OWLS study is a prospective, longitudinal birth cohort study investigating early-life microbiome development and its association with physical and mental health outcomes during childhood. Recruitment began in 2024, enrolling families from late pregnancy through the child's first 6 years of life, with a target of at least 1000- 1200 children and their families. The study characterizes longitudinal microbiome trajectories-including resilience and dysbiosis-and their relationship to common chronic diseases. Data are collected via online surveys, symptom and medication diaries, annual clinical exams, and repeated biological sampling of the child, mother, father/partner, siblings, and household environment. Findings are intended to support future diagnostics, prevention, and therapy for common chronic physical and mental diseases.
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
This Phase 3 study is designed to evaluate the efficacy and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis. Approximately 415 participants will be randomized in a 2:1 ratio to receive roflumilast cream 0.3% or matching vehicle cream during a 4-week double-blind, vehicle-controlled treatment period. Following completion of the double-blind treatment period, all participants will enter a 48-week open-label extension and receive roflumilast cream 0.3%. The study will assess the efficacy of roflumilast cream 0.3% in improving signs and symptoms of atopic dermatitis and evaluate its long-term safety and tolerability through Week 52.
Find Eczema trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.